Monday - April 21, 2025
ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.
The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development.
To instantly join the conference call by phone, use the following link to register close to the call start time: https://emportal.ink/3D1w3vK. After registering, the system will call you and automatically connect you to the conference call. Alternatively, you may join the call by dialing 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator.
A simultaneous webcast of the call and the related presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com/. The replay will be accessible within two hours of the end of the call and will be available for one week. Alternatively, you may dial 1-646-517-4150 or 1-888-660-6345 and enter passcode 27013#.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures, and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
Last Trade: | US$12.43 |
Daily Change: | 0.37 3.07 |
Daily Volume: | 449,773 |
Market Cap: | US$571.280M |
February 26, 2025 November 12, 2024 November 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load